ReviewMedicina (Kaunas, Lithuania)2023

Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection.

Tafadzwa Dzinamarira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.